r michael carruthers cfo nivalis therapeutics timesjavascript is disabled market profiles login sign up login sign up   edit person r michael carruthers cfo at nivalis therapeutics location greater denver area add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop r michael carruthers cfo at nivalis therapeutics location greater denver area add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop r michael carruthers has served as nivalis therapeutics’s chief financial officer and secretary since february   from december  to february  he served as chief financial officer for array biopharma prior to joining array biopharma mr carruthers served as chief financial officer of sievers instrument and before joining sievers was the treasurer and controller for the waukesha division of dover corporation mr carruthers was previously employed as an accountant with coopers  lybrand mr carruthers received a bs in accounting from the university of colorado and a mba from the university of chicago  companies in career na related markets  colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags financial analysis sec filings financial reporting topics of influence na na careers achievements investments related people edit view all r michael carrutherscareer  feb nivalis therapeutics cfo dec to feb array biopharma cfo  to  sievers instruments cfo  to  waukesha bearings corporation controllertreasurer competencies edit view all r michael carrutherseducation  university of colorado boulder accounting edit r michael carruthersachievements and recognitions add milestone no milestones has been recorded for r michael carruthers edit r michael carrutherslinks add link no links has been recorded for r michael carruthers r michael carruthersinvestmentsacquisitions no investments has been recorded for r michael carruthers r michael carruthersinvestments representing others no investment reps has been recorded for r michael carruthers r michael carruthersrelated people colleagues at nivalis therapeutics david m rodman cmo and executive vice president of discovery apr jon congleton president and ceo jan janice troha chief operating officer dec0 steven shoemaker vice president – clinical research and development  medical director jul0 view all peers  wilco groenhuysen chief financial officer of novocure michael gandy chief financial officer of invuity james h mackaness chief financial officer of invuity richard harrison chief financial officer of glaukos sukhi jagpal chief financial officer of pronai therapeutics thomas griffin chief financial officer of entellus medical view all r michael carruthersrecommended market profiles healthcare ipo companies  or more employees  companies n pharmaceuticals appoints r michael carruthers as chief financial officer n pharmaceuticals appoints r michael carruthers as chief financial officer feb    et from n pharmaceuticals inc boulder colo feb   prnewswire  n pharmaceuticals inc n pharma a clinicalstage pharmaceutical company focused on the development of product candidates for cystic fibrosis cf announced today that r michael carruthers has been appointed to the position of chief financial officer cfo  mr carruthers brings more than  years of executivelevel financial expertise to n pharma  most recently mr carruthers served on array biopharma incs executive team as the cfo where he executed the companys initial public offering and multiple followon equity and debt fund raises  mr carruthers is also experienced in strategic planning and managing organizations through rapid growth and with transactions and negotiations involving partnering licensing drug discovery and clinical development  prior to joining array mr carruthers served as cfo of sievers instrument inc and before joining sievers was the treasurer and controller for the waukesha division of dover corporation  mr carruthers was previously employed as an accountant with coopers  lybrand llp  mr carruthers received a bs in accounting from the university of colorado and a mba from the university of chicago mike has an outstanding track record with extensive experience in fund raising and other strategic initiatives for clinicalstage life sciences companies said jon congleton president and chief executive officer of n pharma we welcome him to our team and believe that his capabilities and expertise will greatly benefit n pharma as we pursue our clinical and business objectives n pharma recently secured approximately  million in a private placement of its preferred stock  proceeds from the financing will be used primarily to advance the companys clinical development program for its lead product candidate n which the company is currently developing for patients with cf in a phase  clinical trial i am thrilled to be joining a company with a novel approach to treating cf that may one day improve the lives of patients and i look forward to helping fulfill the potential behind the science said mr carruthers about n n is a novel inhibitor of snitrosoglutathione reductase gsnor n pharma recently completed a phase  doseescalation trial of orally administered n in healthy volunteers no dose limiting toxicities were identified by the data monitoring committee for the trial trials in cf patients with the fdelcftr mutation are now underway in preclinical studies n has been shown to increase the function of fdelcftr the mutant protein that is estimated to be present in almost  percent of cf patients about cystic fibrosis cf is a lifethreatening genetic disease that primarily affects the lungs and digestive system according to the cystic fibrosis foundation wwwcfforg an estimated  children and adults in the united states and  people worldwide have cf cf is characterized by a defect in the chloride channel of human cells known as the cystic fibrosis transmembrane conductance regulator or cftr which is caused by a mutation of the cftr gene cftr is critical for the adequate hydration of the lungs and other organs of the body researchers have identified more than  mutations in the cf gene and it is estimated that approximately  percent of cf patients in the united states have two copies of the fdelcftr mutation and an additional  percent have one copy of this mutation as a consequence of the mutation in the fdelcftr gene patients produce a defective form of cftr protein that fails to adequately transport fluid with n n pharma aims to increase cftr function and restore proper hydration to critical organs particularly the lungs about n pharmaceuticals inc n pharma wwwnpharmacom is a privately held clinicalstage pharmaceutical company headquartered in boulder colorado it is the first company to discover and develop small molecules targeting gsnor n pharma is dedicated to making a difference in the lives of patients with cystic fibrosis and their families media contactlindsay roccolroccoelixirhealthprcom source n pharmaceuticals inc related links httpwwwnpharmacom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more dec  0  et preview n pharmaceuticals appoints jon congleton as president and ceo my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search dns resolution error  irnivaliscom  cloudflare please enable cookies error 0 ray id cbba •  07 utc dns resolution error what happened youve requested a page on a website irnivaliscom that is on the cloudflare network cloudflare is currently unable to resolve your requested domain irnivaliscom there are two potential causes of this most likely if the owner just signed up for cloudflare it can take a few minutes for the websites information to be distributed to our global network less likely something is wrong with this sites configuration usually this happens when accounts have been signed up with a partner organization eg a hosting provider and the providers dns fails cloudflare ray id cbba • your ip  • performance  security by cloudflare r michael carruthers is no longer serving in their position at alpine immune sciences inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology see more news on board and executive moves r michael carruthers is no longer serving in their position at alpine immune sciences inc email linkedin facebook google tweet reddit permalink jul    relsci data update board and executive moves background information r michael carruthers » former chief financial officer at array biopharma inc career alpine immune sciences inc array biopharma inc sievers instruments inc boards amidebio llc pyxant labs inc education the university of colorado university of chicago  booth school of business university of colorado  boulder in the news nivalis therapeutics announces results of special meeting of stockholders july 0   •  business wire nivalis therapeutics reports first quarter  financial results may    •  business wire nivalis therapeutics inc and alpine immune sciences inc agree to combine april    •  business wire r michael carruthers » former chief financial officer at array biopharma inc career • alpine immune sciences inc • array biopharma inc • sievers instruments inc boards • amidebio llc • pyxant labs inc education • the university of colorado • university of chicago  booth school of business • university of colorado  boulder in the news nivalis therapeutics announces results of special meeting of stockholders  july 0   •  business wire nivalis therapeutics reports first quarter  financial results  may    •  business wire nivalis therapeutics inc and alpine immune sciences inc agree to combine  april    •  business wire alpine immune sciences inc » nivalis therapeutics inc is a clinical stage pharmaceutical company which engages in discovery development and commercialization of product for patients with cystic fibrosis its product includes n a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator the company was founded in  and is headquartered in boulder co in the news nivalis therapeutics inc filed form q may    •  sec how these biotech stocks are faring  contravir pharma intracellular therapies nivalis therapeutics and oncosec medical may    •  pr newswire nivalis therapeutics reports first quarter  financial results may    •  business wire alpine immune sciences inc » nivalis therapeutics inc is a clinical stage pharmaceutical company which engages in discovery development and commercialization of product for patients with cystic fibrosis its product includes n a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator the company was founded in  and is headquartered in boulder co in the news nivalis therapeutics inc filed form q  may    •  sec how these biotech stocks are faring  contravir pharma intracellular therapies nivalis therapeutics and oncosec medical  may    •  pr newswire nivalis therapeutics reports first quarter  financial results  may    •  business wire see more news on board and executive moves youve found a premium relsci pro feature connect to individuals and organizations in this story upgrade to relsci pro to easily sync your contacts and see how you can reach the people and organizations featured in this article start my free trial ➤ still not convinced check out our full listing of features here not now are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ page not found  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for 0 commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use 6 thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street page not found sorry the page youre looking for is not available you might want to try our homepage our most popular stories 6 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers n pharmaceuticals appoints r michael carruthers as chief financial officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       n pharmaceuticals appoints r michael carruthers as chief financial officer tweet  0 am boulder colo feb   prnewswire  n pharmaceuticals inc n pharma a clinicalstage pharmaceutical company focused on the development of product candidates for cystic fibrosis cf announced today that r michael carruthers has been appointed to the position of chief financial officer cfo  mr carruthers brings more than  years of executivelevel financial expertise to n pharma  most recently mr carruthers served on array biopharma incs executive team as the cfo where he executed the companys initial public offering and multiple followon equity and debt fund raises  mr carruthers is also experienced in strategic planning and managing organizations through rapid growth and with transactions and negotiations involving partnering licensing drug discovery and clinical development  prior to joining array mr carruthers served as cfo of sievers instrument inc and before joining sievers was the treasurer and controller for the waukesha division of dover corporation  mr carruthers was previously employed as an accountant with coopers  lybrand llp  mr carruthers received a bs in accounting from the university of colorado and a mba from the university of chicagomike has an outstanding track record with extensive experience in fund raising and other strategic initiatives for clinicalstage life sciences companies said jon congleton president and chief executive officer of n pharma we welcome him to our team and believe that his capabilities and expertise will greatly benefit n pharma as we pursue our clinical and business objectivesn pharma recently secured approximately  million in a private placement of its preferred stock  proceeds from the financing will be used primarily to advance the companys clinical development program for its lead product candidate n which the company is currently developing for patients with cf in a phase  clinical trial i am thrilled to be joining a company with a novel approach to treating cf that may one day improve the lives of patients and i look forward to helping fulfill the potential behind the science said mr carruthers about nn is a novel inhibitor of snitrosoglutathione reductase gsnor n pharma recently completed a phase  doseescalation trial of orally administered n in healthy volunteers no dose limiting toxicities were identified by the data monitoring committee for the trial trials in cf patients with the fdelcftr mutation are now underway in preclinical studies n has been shown to increase the function of fdelcftr the mutant protein that is estimated to be present in almost  percent of cf patients about cystic fibrosis cf is a lifethreatening genetic disease that primarily affects the lungs and digestive system according to the cystic fibrosis foundation wwwcfforg an estimated  children and adults in the united states and  people worldwide have cfcf is characterized by a defect in the chloride channel of human cells known as the cystic fibrosis transmembrane conductance regulator or cftr which is caused by a mutation of the cftr gene cftr is critical for the adequate hydration of the lungs and other organs of the body researchers have identified more than  mutations in the cf gene and it is estimated that approximately  percent of cf patients in the united states have two copies of the fdelcftr mutation and an additional  percent have one copy of this mutation as a consequence of the mutation in the fdelcftr gene patients produce a defective form of cftr protein that fails to adequately transport fluid with n n pharma aims to increase cftr function and restore proper hydration to critical organs particularly the lungs about n pharmaceuticals inc n pharma wwwnpharmacom is a privately held clinicalstage pharmaceutical company headquartered in boulder colorado it is the first company to discover and develop small molecules targeting gsnor n pharma is dedicated to making a difference in the lives of patients with cystic fibrosis and their families media contactlindsay roccolroccoelixirhealthprcomto view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesnpharmaceuticalsappointsrmichaelcarruthersaschieffinancialofficer7htmlsource n pharmaceuticals inc help employers find you check out all the jobs and post your resume read at biospacecom related news spurred by biotechs rapid growth banking giant taps firstever boston staffer to focus on supercluster ousted sanofi sanpa ceo pockets  million severance package large acucela inc shareholder wants to oust four out of five board members bristolmyers squibb bmy names caforio as new ceo effective may  three rejections on the board fruitless ceo hunt overshadows sanofi sanpa aegerion aegr stays mum as top investors push to oust ceo consider sale huge payday looming for six auxilium pharmaceuticals auxl execs after  billion sale to roche rhhby intermune inc itmn chief jumps to venture capital takeda tkpyy coo was approached for sanofi sanpa ceo job but declined breaking jp morgan sanofi sanpa says afrezza will be available in  snubs mannkind corporation mnkd ceo retirement news please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom   • biotechpharma  personnel                 n pharmaceuticals appoints r michael carruthers as chief financial officer  the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases n pharmaceuticals appoints r michael carruthers as chief financial officer feb   am est boulder colo feb   prnewswire  n pharmaceuticals inc n pharma a clinicalstage pharmaceutical company focused on the development of product candidates for cystic fibrosis cf announced today that r michael carruthers has been appointed to the position of chief financial officer cfo  mr carruthers brings more than  years of executivelevel financial expertise to n pharma  most recently mr carruthers served on array biopharma incs executive team as the cfo where he executed the companys initial public offering and multiple followon equity and debt fund raises  mr carruthers is also experienced in strategic planning and managing organizations through rapid growth and with transactions and negotiations involving partnering licensing drug discovery and clinical development  prior to joining array mr carruthers served as cfo of sievers instrument inc and before joining sievers was the treasurer and controller for the waukesha division of dover corporation  mr carruthers was previously employed as an accountant with coopers  lybrand llp  mr carruthers received a bs in accounting from the university of colorado and a mba from the university of chicago mike has an outstanding track record with extensive experience in fund raising and other strategic initiatives for clinicalstage life sciences companies said jon congleton president and chief executive officer of n pharma we welcome him to our team and believe that his capabilities and expertise will greatly benefit n pharma as we pursue our clinical and business objectives n pharma recently secured approximately  million in a private placement of its preferred stock  proceeds from the financing will be used primarily to advance the companys clinical development program for its lead product candidate n which the company is currently developing for patients with cf in a phase  clinical trial i am thrilled to be joining a company with a novel approach to treating cf that may one day improve the lives of patients and i look forward to helping fulfill the potential behind the science said mr carruthers about n n is a novel inhibitor of snitrosoglutathione reductase gsnor n pharma recently completed a phase  doseescalation trial of orally administered n in healthy volunteers no dose limiting toxicities were identified by the data monitoring committee for the trial trials in cf patients with the fdelcftr mutation are now underway in preclinical studies n has been shown to increase the function of fdelcftr the mutant protein that is estimated to be present in almost  percent of cf patients about cystic fibrosis cf is a lifethreatening genetic disease that primarily affects the lungs and digestive system according to the cystic fibrosis foundation wwwcfforg an estimated  children and adults in the united states and  people worldwide have cf cf is characterized by a defect in the chloride channel of human cells known as the cystic fibrosis transmembrane conductance regulator or cftr which is caused by a mutation of the cftr gene cftr is critical for the adequate hydration of the lungs and other organs of the body researchers have identified more than  mutations in the cf gene and it is estimated that approximately  percent of cf patients in the united states have two copies of the fdelcftr mutation and an additional  percent have one copy of this mutation as a consequence of the mutation in the fdelcftr gene patients produce a defective form of cftr protein that fails to adequately transport fluid with n n pharma aims to increase cftr function and restore proper hydration to critical organs particularly the lungs about n pharmaceuticals inc n pharma wwwnpharmacom is a privately held clinicalstage pharmaceutical company headquartered in boulder colorado it is the first company to discover and develop small molecules targeting gsnor n pharma is dedicated to making a difference in the lives of patients with cystic fibrosis and their families media contactlindsay roccolroccoelixirhealthprcom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesnpharmaceuticalsappointsrmichaelcarruthersaschieffinancialofficer7html source n pharmaceuticals inc the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more r m carruthers  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in r m carruthers chief financial officer and interim president at nivalis therapeutics inc view full profile are you r m carruthers claim your profile   sign up for equilar atlas and view r m carrutherss full profile with equilar atlas you can identify corporate executives in r m carrutherss network and community follow changes in r m carrutherss employment and moneyinmotion connect with r m carruthers through your network of contacts r m carrutherss executive work history current chief financial officer and interim president nivalis therapeutics inc past to view r m carrutherss complete executive work history sign up now age      sign up for equilar atlas and view r m carrutherss full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like r m carruthers more specifically youll be able to identify corporate executives in r m carrutherss network and community follow changes in r m carrutherss employment and moneyinmotion connect with r m carruthers through your network of conections view full profile   search for over 60 executive profiles bio example r m carruthers r m carrutherss connections  sign up now to view r m carrutherss  connections » michael n needle chief medical officer aveo pharmaceuticals inc david l snitman former consultant array biopharma inc john a orwin dir president and chief executive officer relypsa inc liam ratcliffe former board member edge therapeutics inc gil j van lunsen board member array biopharma inc ron squarer dir and chief executive officer array biopharma inc robert w overell dir president and chief executive officer phaserx inc kyle a lefkoff chairman array biopharma inc john l zabriskie former board member array biopharma inc john r moore vice president general counsel and secretary array biopharma inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca 6  phone 60 66  fax 60 0